(E/Z)-1-(2-(2-((2-nitro-9H-fluoren-9-ylidene)methyl)phenoxy)ethyl)piperazine

ID: ALA4483533

PubChem CID: 71271357

Max Phase: Preclinical

Molecular Formula: C26H25N3O3

Molecular Weight: 427.50

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  O=[N+]([O-])c1ccc2c(c1)C(=Cc1ccccc1OCCN1CCNCC1)c1ccccc1-2

Standard InChI:  InChI=1S/C26H25N3O3/c30-29(31)20-9-10-23-21-6-2-3-7-22(21)24(25(23)18-20)17-19-5-1-4-8-26(19)32-16-15-28-13-11-27-12-14-28/h1-10,17-18,27H,11-16H2

Standard InChI Key:  JLPXBELNAFBHCZ-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 32 36  0  0  0  0  0  0  0  0999 V2000
   25.7975   -4.6851    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.3902   -5.9649    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.1288   -5.1791    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.3237   -5.0095    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.7793   -5.6205    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.0331   -6.3997    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.8376   -6.5781    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.4708   -5.1781    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.2154   -5.9623    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   26.7557   -6.5798    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.5637   -6.4018    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.8288   -5.6217    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.2745   -5.0117    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.7958   -3.8580    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.0770   -3.4522    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   25.0775   -2.6256    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.3596   -2.2074    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.6415   -2.6287    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.6459   -3.4600    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   24.3644   -3.8621    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.6407   -5.4437    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   28.8926   -4.6565    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   29.1857   -6.0616    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   25.7915   -2.2102    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   26.5052   -2.6261    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.2191   -2.2108    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   27.9328   -2.6267    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   27.9299   -3.4497    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.6395   -3.8572    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.3476   -3.4536    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   29.3498   -2.6297    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.6441   -2.2094    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  9  1  0
  8  1  1  0
  1  3  1  0
  2  3  2  0
  3  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  2  1  0
  8  9  2  0
  9 10  1  0
 10 11  2  0
 11 12  1  0
 12 13  2  0
 13  8  1  0
  1 14  2  3
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 20 15  1  0
 21 22  2  0
 21 23  1  0
 12 21  1  0
 16 24  1  0
 24 25  1  0
 25 26  1  0
 26 27  1  0
 27 28  1  0
 27 32  1  0
 28 29  1  0
 29 30  1  0
 30 31  1  0
 31 32  1  0
M  CHG  2  21   1  23  -1
M  END

Alternative Forms

1. Parent:

   

   ALA4483533

   1-[2-[2-[(2-Nitrofluoren-9-ylidene)methyl]phenoxy]ethyl]piperazine

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 427.50

Molecular Weight (Monoisotopic): 427.1896

AlogP: 4.45

#Rotatable Bonds: 6

Polar Surface Area: 67.64

Molecular Species: BASE

HBA: 5

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 9.23

CX LogP: 4.69

CX LogD: 2.87

Aromatic Rings: 3

Heavy Atoms: 32

QED Weighted: 0.36

Np Likeness Score: -1.22

References

1. Liu G, Yin T, Kim H, Ding C, Yu Z, Wang H, Chen H, Yan R, Wold EA, Zou H, Liu X, Ding Y, Shen Q, Zhou J..  (2019)  Structure-activity relationship studies on Bax activator SMBA1 for the treatment of ER-positive and triple-negative breast cancer.,  178  [PMID:31220676] [10.1016/j.ejmech.2019.06.004]

Source

Source(1):

• Scientific Literature